# A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

> **NCT06662786** · PHASE3 · RECRUITING · sponsor: **Janssen Research & Development, LLC** · enrollment: 1000 (estimated)

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **BIOLOGICAL:** Amivantamab
- **BIOLOGICAL:** Cetuximab
- **DRUG:** 5-fluorouracil
- **DRUG:** Leucovorin calcium/Levoleucovorin
- **DRUG:** Oxaliplatin
- **DRUG:** Irinotecan Hydrochloride

## Key facts

- **NCT ID:** NCT06662786
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-18
- **Primary completion:** 2028-12-15
- **Final completion:** 2032-01-20
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06662786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06662786, "A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer". Retrieved via AI Analytics 2026-08-13 from https://api.ai-analytics.org/clinical/NCT06662786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*